D. Schneck

发表

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

C. Locke, L. Gustavson, J. F. Kaiser, 1995, Antimicrobial agents and chemotherapy.

A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

T. Bjornsson, J. Wagner, D. Sonnichsen, 2003, Journal of clinical pharmacology.

Studies on the uptake and binding of propranolol by rat tissues.

J. Pritchard, D. Schneck, A. Hayes, 1977, The Journal of pharmacology and experimental therapeutics.

Disposition of a murine monoclonal antibody vinca conjugate (KS1/4‐DAVLB) in patients with adenocarcinomas

R. Bowsher, D. Schneck, W. Dugan, 1990, Clinical pharmacology and therapeutics.

effect of gemfibrozil on the harmacokinetics of rosuvastatin

Paul D. Martin, K. Lasseter, D. Schneck, 2022 .

PHARMACOKINETICS AND DISPOSITION Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment

S. G. Simonson, K. Lasseter, P. Martin, 2003 .

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.

Paul D. Martin, A. Dane, A. Raza, 2003, British journal of clinical pharmacology.

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.

Paul D. Martin, D. Schneck, M. Warwick, 2004, British journal of clinical pharmacology.

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.

Paul D. Martin, D. Schneck, P. Mitchell, 2002, British journal of clinical pharmacology.

Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522

A. Dane, A. Raza, D. Schneck, 2000 .

The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.

B. H. Petersen, T. Bumol, D. Schneck, 1991, Cancer research.

A pharmacokinetic profile of nizatidine in man.

W W Offen, W. Offen, G. Aronoff, 1987, Scandinavian journal of gastroenterology. Supplement.

Relationship between steady‐state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

W. Offen, R. Bergstrom, J. Callaghan, 1990, Clinical pharmacology and therapeutics.

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

D. Rader, D. Hunninghake, E. Stein, 2004, Coronary artery disease.

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor

Paul D. Martin, A. Dane, D. Schneck, 2002, Journal of clinical pharmacology.

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

Paul D. Martin, T. Tzeng, D. Schneck, 2008 .

Propranolol rebound--a retrospective study.

D. Leaman, R. Shiroff, R. Zelis, 1978, The American journal of cardiology.

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Paul D. Martin, A. Dane, D. Schneck, 2008 .

Effects of ethanol and phenobarbital on the metabolism of propranolol by 9000 g rat liver supernatant.

J. Pritchard, D. Schneck, 1977, Biochemical pharmacology.

Studies of the relationship between chemical structure and porphyria-inducing activity. IV. Investigations in a cell culture system.

G. Hirsch, G. S. Marks, W. J. Racz, 1968, Biochemical pharmacology.

Studies of the relationship between chemical structure and porphyria-inducing activity.

G. S. Marks, D. Schneck, E. G. Hunter, 1965, Biochemical pharmacology.

The inhibitory effect of propranolol pretreatment on its own metabolism in the rat.

J. Pritchard, D. Schneck, 1981, The Journal of pharmacology and experimental therapeutics.

Captopril‐Induced Skin Eruptions

C. Cohen, L. Demers, D. Lookingbill, 1982, Journal of clinical pharmacology.

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Paul D. Martin, A. Dane, Paul D. Martin, 2003, Clinical pharmacology and therapeutics.

Plasma levels of free and acid‐labile hydralazine: Effects of multiple dosing and of procainamide

D. Schneck, J. Sprouse, A. Hayes, 1978, Clinical pharmacology and therapeutics.

Age and ceftriaxone kinetics

I. Patel, D. Schneck, J. Luderer, 1984, Clinical pharmacology and therapeutics.

Drug-induced porphyrin biosynthesis. 3. Inhibition of drug-induced porphyria by protohemin.

D. Tyrrell, G. S. Marks, D. Schneck, 1971, Biochemical pharmacology.

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Paul D. Martin, Ali Raza, J. Jarcho, 2004, Clinical pharmacology and therapeutics.

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Paul D. Martin, K. Lasseter, A. Raza, 2004, Clinical pharmacology and therapeutics.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

R. Davidson, G. Holdgate, A. McCormick, 2001, The American journal of cardiology.

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.

R. McPherson, C. Ballantyne, R. Knopp, 2003, The American journal of cardiology.

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Caroline A. Lee, Yusong Chen, E. Lee, 2005, Clinical pharmacology and therapeutics.

Increased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjects

Yusong Chen, D. Schneck, Kenneth T. Kim, 2008 .

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia.

T. Tzeng, D. Schneck, B. Birmingham, 2008, Current medical research and opinion.

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.

Paul D. Martin, A. Dane, D. Schneck, 2003, Clinical therapeutics.

The effect of fluconazole on the pharmacokinetics of rosuvastatin

A. Dane, M. Cantarini, D. Schneck, 2002, European Journal of Clinical Pharmacology.

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Paul D. Martin, K. Lasseter, D. Schneck, 2005, Journal of clinical pharmacology.

Effect of dose and uremia on plasma and urine profiles of propranolol metabolites

J. Pritchard, D. Schneck, T. Gibson, 1980, Clinical pharmacology and therapeutics.

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.

G. Granneman, J. Cavanaugh, D. Schneck, 1996, The Journal of clinical psychiatry.

Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography.

J. Pritchard, D. Schneck, A. Hayes, 1979, Journal of chromatography.

Mechanism by which hydralazine increases propranolol bioavailability

D. Schneck, J. Vary, Dennis W Schneck, 1984, Clinical pharmacology and therapeutics.

The effect of erythromycin on the pharmacokinetics of rosuvastatin

Paul D. Martin, A. Dane, A. Raza, 2003, European Journal of Clinical Pharmacology.

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Paul D. Martin, J. Kemp, A. Dane, 2002, Journal of clinical pharmacology.

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

G. Nicholas, D. Schneck, J. Luderer, 1984, Clinical pharmacology and therapeutics.

The contribution of propranolol metabolites to the fluorometric assay of propranolol in human plasma.

W. J. Racz, J. Pritchard, D. Schneck, 1978, Clinical biochemistry.

Measurement of propranolol, 4-hydroxypropranolol and propranolol glycol in human plasma.

J. Pritchard, D. Schneck, A. Hayes, 1979, Research communications in chemical pathology and pharmacology.